Zacks Research Analysts Boost Earnings Estimates for UTHR

United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Zacks Research upped their Q4 2024 earnings per share estimates for shares of United Therapeutics in a research report issued to clients and investors on Tuesday, November 19th. Zacks Research analyst R. Department now anticipates that the biotechnology company will earn $6.04 per share for the quarter, up from their prior estimate of $5.40. The consensus estimate for United Therapeutics’ current full-year earnings is $25.22 per share. Zacks Research also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.74 EPS, FY2025 earnings at $27.64 EPS, Q3 2026 earnings at $7.15 EPS and FY2026 earnings at $26.89 EPS.

A number of other research firms have also recently weighed in on UTHR. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Bank of America cut their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. The Goldman Sachs Group raised their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $372.89 on Friday. The firm has a market capitalization of $16.65 billion, a PE ratio of 16.38, a PEG ratio of 1.07 and a beta of 0.56. The stock’s fifty day moving average is $365.06 and its 200 day moving average is $331.82. United Therapeutics has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.38 EPS.

Insider Activity at United Therapeutics

In other news, Director Judy D. Olian sold 1,750 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the sale, the director now directly owns 5,655 shares in the company, valued at $2,332,574.40. The trade was a 23.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher Causey sold 510 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the transaction, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. The trade was a 12.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 117,496 shares of company stock worth $43,765,042 in the last three months. Company insiders own 11.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of UTHR. Comerica Bank lifted its position in shares of United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after acquiring an additional 9,244 shares in the last quarter. Tri Locum Partners LP purchased a new position in United Therapeutics in the 2nd quarter valued at $15,959,000. QRG Capital Management Inc. boosted its stake in United Therapeutics by 12.4% during the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of United Therapeutics by 567.2% during the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after buying an additional 153,700 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of United Therapeutics by 1.1% in the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after buying an additional 22,978 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.